Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Serena Williams revealed she lost 31 pounds using GLP-1 weight-loss drugs over the course of one year, sparking conversations ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...

The global glucagon-like peptide 1 market is expected to grow from $18.11 billion in 2022 to $19.51 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%.

Serena Williams, the 43-year-old tennis icon and 23-time Grand Slam champion opened up about her weight loss journey with the ...

The metabolism of GLP-1 in the body is extremely rapid and the peptide gets inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), even before leaving the gut. 3 Glucagon is a key hormone in ...

Glucagon-like-peptide-1 (GLP1) analogs may induce thyroid or pancreatic diseases in animals, raising questions about their use in diabetic patients. There is, however, controversy regarding ...

The glucagon-like peptide 1 (GLP-1) market is projected to grow at a CAGR of 6.48%, during the forecast period of 2022-2027.